GlassScriptPhysician profile
Sharon Yun Chen
NPI 1306675590
$1,895.46
in general payments reported to CMS, 2019-2025
21 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $319 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.29 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $252.54 | 2024-2025 | |
| Pfizer INC. | $246.99 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $138.47 | 2025 | Contrave |
| Lilly USA, LLC | $108.56 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $106.25 | 2025 | |
| Novo Nordisk INC | $93.62 | 2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.98 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $68.54 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $55.84 | 2025 | |
| Glaxosmithkline, LLC. | $46.30 | 2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $44.57 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $43.08 | 2024-2025 | Aptima |
| Amgen INC. | $40.39 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $35.64 | 2025 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.48 | 2025 | Auvelity |
| Gilead Sciences, INC. | $29.32 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.82 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $21.00 | 2025 | Voquezna |
| Medtronic, INC. | $19.00 | 2025 | Inceptiv |
| Phadia US INC. | $13.78 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.